The Central Drug Standards Control Organisation (CDSCO) has conducted raids at two firms based in Haridwar and Roorkee and is mulling cancellation of their licenses for manufacturing and selling medicines without approval from the drug regulator, officials said today.
The two companies were apparently found to be manufacturing and selling fixed dose combination for treatment of diabetes and fungal infection without the permission from Drug Controller General of India (DCGI).
DCGI official said two separate teams of CDSCO raided the premises of the two firms in coordination with the state drug control officials of Uttarakhand and local police officials yesterday.
During the raids, the teams found that both the firms were involved in manufacturing fixed dose combination which are not yet approved under the Drugs and Cosmetics Act, 1940, he said, adding drugs worth Rs 3 lakh were seized.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app